Clinical Trial Update: Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of arsenic trioxide and thalidomide in patients with refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)
• Thalidomide (thalidomide)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED